Targeted treatment for her2-positive colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called TQB2102 for colorectal cancer that has HER2-positive tumors and has stopped responding to standard treatments. The drug targets HER2 to try to slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced colorectal cancer that has gotten worse after at least 2 different standard treatments.
- Your tumor must test positive for HER2 (a specific protein) – your doctor can check a recent biopsy sample.
- You are able to do light activities and take care of yourself (do not need bed rest most of the day).
- You have at least one tumor that can be measured on a scan.
- You must be willing to use birth control during the study and for 6 months after, if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
This trial tests a new drug, TQB2102, for people with advanced bile duct cancer that has HER2 protein markers. It aims to see if the drug can help when previous treatments haven't worked.
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
This trial tests a new drug called TQB2922 combined with TAS-102, with or without bevacizumab, for people whose advanced colorectal cancer has a normal RAS and BRAF gene and has not responded to standard chemotherapy. The goal is to see if this combination can slow or stop cancer growth.
Hear when a new HER2 IHC3+ Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.